{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:44:18Z","timestamp":1775198658970,"version":"3.50.1"},"reference-count":109,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00511\/2020"],"award-info":[{"award-number":["UIDB\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/00511\/2020"],"award-info":[{"award-number":["UIDP\/00511\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["ALiCE, LA\/P\/0045\/2020"],"award-info":[{"award-number":["ALiCE, LA\/P\/0045\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["CEEC-IND\/01741\/2021"],"award-info":[{"award-number":["CEEC-IND\/01741\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["M-ERA-NET3\/0001\/2021"],"award-info":[{"award-number":["M-ERA-NET3\/0001\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Glioblastoma (GBM) remains the most aggressive primary brain tumor, with poor outcomes under the current standard-of-care with temozolomide (TMZ). Therapeutic failure is multifactorial, mainly driven by TMZ resistance mediated by DNA repair enzymes (MGMT), and an immunosuppressive tumor microenvironment. Drug repurposing and the off-label use of chemotherapeutics have emerged as a strategy to identify non-alkylating agents capable of bypassing MGMT-mediated resistance in GBM. Despite their promise, the effective delivery of these drugs to the brain remains a major challenge due to the low-permeability nature of the blood\u2013brain barrier (BBB). Thus, surface-modified polymeric nanoparticles (NPs) have emerged as adaptable platforms for encapsulating chemically diverse payloads, thereby improving their pharmacokinetics and enabling controlled release at the tumor site. This review critically analyzes ligand-functionalized polymeric NPs for GBM therapy and discusses the integration of repurposed and off-label non-alkylating agents with nanocarrier engineering, focusing on non-alkylating agents as they are MGMT-independent candidates. Furthermore, this review synthesizes recent advances in ligand-functionalized polymeric nanoformulations encapsulating non-alkylating agents for GBM, critically outlining their targeting and transport strategies, design and validation challenges, and future directions. Across the included studies, receptor-targeted surface engineering frequently enhances cellular uptake and in vitro efficacy.<\/jats:p>","DOI":"10.3390\/pharmaceutics18040435","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:09:21Z","timestamp":1775038161000},"page":"435","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surface-Modified Polymeric Nanoparticles for Glioblastoma Therapy: A Review on Targeting Strategies and Delivery of Repurposed Drugs and Off-Label Non-Alkylating Agents"],"prefix":"10.3390","volume":"18","author":[{"given":"Daniela Maria","family":"Sousa","sequence":"first","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9841-3967","authenticated-orcid":false,"given":"Joana Ang\u00e9lica","family":"Loureiro","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"},{"name":"Department of Metallurgical and Materials Engineering, Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-3432","authenticated-orcid":false,"given":"Maria Carmo","family":"Pereira","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-7520","authenticated-orcid":false,"given":"Maria Jo\u00e3o","family":"Ramalho","sequence":"additional","affiliation":[{"name":"LEPABE\u2014Laboratory for Process Engineering, Environment, Biotechnology and Energy, ALiCE\u2014Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wang, K. (2025). Innovative Nanoparticle-Based Therapeutic Strategies against Glioblastoma Multiform: A Focus on Enhanced Delivery Systems and Efficacy. Front. Bioeng. Biotechnol., 13.","DOI":"10.3389\/fbioe.2025.1601673"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Angom, R.S., Nakka, N.M.R., and Bhattacharya, S. (2023). Advances in Glioblastoma Therapy: An Update on Current Approaches. Brain Sci., 13.","DOI":"10.3390\/brainsci13111536"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000990","article-title":"Unveiling the Enigma of the Blood\u2013Brain Barrier in Glioblastoma: Current Advances from Preclinical and Clinical Studies","volume":"35","author":"Ahmed","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117276","DOI":"10.1016\/j.bcp.2025.117276","article-title":"A Modern Approach to Glioblastoma Using Temozolomide and Nanoparticles Carrier Drug: A Standard Care of Combination Therapy and Treatment","volume":"242","author":"Rahman","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alomari, S., Tyler, B., Zhang, I., Hernandez, A., Kraft, C.Y., Raj, D., and Kedda, J. (2021). Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery\u2014A Comprehensive Review of the Literature. Biomolecules, 11.","DOI":"10.3390\/biom11121870"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug Repositioning: A Brief Overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kheir, W.E., Marcos, B., Virgilio, N., Paquette, B., Faucheux, N., and Lauzon, M.A. (2022). Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061189"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic Nanoparticles for Drug Delivery in Cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1007\/s10072-025-08457-4","article-title":"Advancing Glioblastoma Therapy with Surface-Modified Nanoparticles","volume":"46","author":"Zeppieri","year":"2025","journal-title":"Neurol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liu, S., Tan, B., Wang, F., and Yu, Y. (2024). Applications of Polymeric Nanoparticles in Drug Delivery for Glioblastoma. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1519479"},{"key":"ref_11","unstructured":"(2026, January 19). Glioblastoma: Gliocure. Available online: www.gliocure.com\/en\/patients\/glioblastoma\/."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"De Vleeschouwer, S. (2017). Epidemiology and Outcome of Glioblastoma. Glioblastoma, Codon Publications.","DOI":"10.15586\/codon.glioblastoma.2017"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.29337\/ijsp.148","article-title":"Global Landscape of Glioblastoma Multiforme Management in the Stupp Protocol Era: Systematic Review Protocol","volume":"25","author":"Adegboyega","year":"2021","journal-title":"Int. J. Surg. Protoc."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Grochans, S., Cybulska, A.M., Simi\u0144ska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme\u2013Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14102412"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10072-011-0797-8","article-title":"Loco-Regional Treatments in First-Diagnosis Glioblastoma: Literature Review on Association between Stupp Protocol and Gliadel","volume":"32","author":"Salmaggi","year":"2011","journal-title":"Neurol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jconrel.2022.08.024","article-title":"Polymeric and Small Molecule-Conjugates of Temozolomide as Improved Therapeutic Agents for Glioblastoma Multiforme","volume":"350","author":"Jatyan","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Harder, B.G., Blomquist, M.R., Wang, J., Kim, A.J., Woodworth, G.F., Winkles, J.A., Loftus, J.C., and Tran, N.L. (2018). Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00462"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hersh, A.M., Alomari, S., and Tyler, B.M. (2022). Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084153"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2018.04.062","article-title":"Receptor-Mediated PLGA Nanoparticles for Glioblastoma Multiforme Treatment","volume":"545","author":"Ramalho","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12951-021-01002-3","article-title":"Combination of Cell-Penetrating Peptides with Nanomaterials for the Potential Therapeutics of Central Nervous System Disorders: A Review","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/17435889.2025.2503694","article-title":"Recent Advances in Nanomaterial-Based Brain-Targeted Delivery Systems for Glioblastoma Therapy","volume":"20","author":"Qu","year":"2025","journal-title":"Nanomedicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8013575","DOI":"10.1155\/2017\/8013575","article-title":"Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives","volume":"2017","author":"Szopa","year":"2017","journal-title":"BioMed Res. Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tripathy, D.K., Panda, L.P., Biswal, S., and Barhwal, K. (2024). Insights into the Glioblastoma Tumor Microenvironment: Current and Emerging Therapeutic Approaches. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1355242"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Feldman, L. (2024). Hypoxia within the Glioblastoma Tumor Microenvironment: A Master Saboteur of Novel Treatments. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1384249"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jiang, D., and Li, Y. (2025). Unraveling the Immunosuppressive Microenvironment of Glioblastoma and Advancements in Treatment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1590781"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wei, R., Zhou, J., Bui, B., and Liu, X. (2024). Glioma Actively Orchestrate a Self-Advantageous Extracellular Matrix to Promote Recurrence and Progression. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12751-3"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Vanbilloen, W.J.F., Rechberger, J.S., Anderson, J.B., Nonnenbroich, L.F., Zhang, L., and Daniels, D.J. (2023). Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood\u2013Brain Barrier to Treat Brain Tumors. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071804"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Eker, F., Duman, H., Akda\u015f\u00e7i, E., Bolat, E., Sar\u0131ta\u015f, S., Karav, S., and Witkowska, A.M. (2024). A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity. Molecules, 29.","DOI":"10.3390\/molecules29153482"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ramalho, M.J., Loureiro, J.A., Coelho, M.A.N., and Pereira, M.C. (2022). Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020279"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ramalho, M.J., N\u00f3brega, C., Andrade, S., Lima, J., Loureiro, J.A., and Pereira, M.C. (2025). Targeted Fluoxetine Delivery Using Folic Acid-Modified PLGA Nanoparticles for Selective Uptake by Glioblastoma Cells. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091116"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., and Agostini, M. (2020). Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of \u201cStealthy\u201d Nanomaterials. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.00166"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-019-00631-4","article-title":"PEGylation: A Promising Strategy to Overcome Challenges to Cancer-Targeted Nanomedicines: A Review of Challenges to Clinical Transition and Promising Resolution","volume":"9","author":"Hussain","year":"2019","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Makharadze, D., del Valle, L.J., Katsarava, R., and Puiggal\u00ed, J. (2025). The Art of PEGylation: From Simple Polymer to Sophisticated Drug Delivery System. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202502.0191.v1"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1002\/mco2.327","article-title":"Nanoparticles-induced Potential Toxicity on Human Health: Applications, Toxicity Mechanisms, and Evaluation Models","volume":"4","author":"Xuan","year":"2023","journal-title":"MedComm"},{"key":"ref_37","unstructured":"(2026, January 02). University of Illinois Urbana-Champaign Study Reveals Optimal Particle Size for Anticancer Nanomedicines. Available online: https:\/\/Grainger.Illinois.Edu\/News\/Stories\/28309."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"189109","DOI":"10.1016\/j.bbcan.2024.189109","article-title":"Augmentation of the EPR Effect by Mild Hyperthermia to Improve Nanoparticle Delivery to the Tumor","volume":"1879","author":"Aloss","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"El-Hammadi, M.M., and Arias, J.L. (2022). Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines. Nanomaterials, 12.","DOI":"10.3390\/nano12030354"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liu, S.F., Li, M.J., Liang, B., Sun, W., Shao, Y., Hu, X., and Xing, D. (2024). Breaking the Barrier: Nanoparticle-Enhanced Radiotherapy as the New Vanguard in Brain Tumor Treatment. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1394816"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbrc.2015.06.137","article-title":"Effective Treatment of Glioblastoma Requires Crossing the Blood\u2013Brain Barrier and Targeting Tumors Including Cancer Stem Cells: The Promise of Nanomedicine","volume":"468","author":"Kim","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1021\/acs.molpharmaceut.5b00222","article-title":"Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin\/Transferrin Receptor Complex","volume":"12","author":"Kang","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijbiomac.2017.08.155","article-title":"Lactoferrin Functionalized PEG-PLGA Nanoparticles of Shikonin for Brain Targeting Therapy of Glioma","volume":"107","author":"Li","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41467-017-01392-9","article-title":"Interleukin-13 Receptor Alpha 2 Cooperates with EGFRvIII Signaling to Promote Glioblastoma Multiforme","volume":"8","author":"Newman","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.stem.2020.04.008","article-title":"The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma","volume":"26","author":"Vora","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s11095-021-03050-8","article-title":"Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma\u2014In Vitro Evaluation in Glioblastoma Stem Cells","volume":"38","author":"Smiley","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1021\/acs.molpharmaceut.5c00229","article-title":"CRGD-Functionalized Nanohybrid Conjugates Codelivering Temozolomide and Rapamycin for Treating Glioblastoma Multiforme: In Vitro and In Vivo Evaluation","volume":"22","author":"Singh","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramalho, M.J., Alves, B., Andrade, S., Lima, J., Loureiro, J.A., and Pereira, M.C. (2024). Folic-Acid-Conjugated Poly (Lactic-Co-Glycolic Acid) Nanoparticles Loaded with Gallic Acid Induce Glioblastoma Cell Death by Reactive-Oxygen-Species-Induced Stress. Polymers, 16.","DOI":"10.3390\/polym16152161"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2014.12.070","article-title":"Targeting Delivery of Etoposide to Inhibit the Growth of Human Glioblastoma Multiforme Using Lactoferrin- and Folic Acid-Grafted Poly(Lactide-Co-Glycolide) Nanoparticles","volume":"479","author":"Kuo","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12951-024-02531-3","article-title":"Dual-Targeted Delivery of Temozolomide by Multi-Responsive Nanoplatform via Tumor Microenvironment Modulation for Overcoming Drug Resistance to Treat Glioblastoma","volume":"22","author":"Chen","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5650\/jos.ess24085","article-title":"Transferrin-Modified Gemcitabine Encapsulated Polymeric Nanoparticles Persuaded Apoptosis in U87MG Cells and Improved Drug Availability in Rat Brain: An Active Targeting Strategy for Treatment of Glioma","volume":"74","author":"Kumar","year":"2025","journal-title":"J. Oleo Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s11095-010-0091-0","article-title":"Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(\u03b2-L-Malic Acid)","volume":"27","author":"Patil","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpharm.2013.07.019","article-title":"T7 Peptide-Functionalized Nanoparticles Utilizing RNA Interference for Glioma Dual Targeting","volume":"454","author":"Kuang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1016\/j.biomaterials.2013.08.039","article-title":"LDLR-Mediated Peptide-22-Conjugated Nanoparticles for Dual-Targeting Therapy of Brain Glioma","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.2147\/IJN.S257459","article-title":"Transferrin Receptor-Targeted Peg-Pla Polymeric Micelles for Chemotherapy against Glioblastoma Multiforme","volume":"15","author":"Sun","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10611861003734001","article-title":"Targeting the Insulin Receptor: Nanoparticles for Drug Delivery across the Blood-Brain Barrier (BBB)","volume":"19","author":"Ulbrich","year":"2011","journal-title":"J. Drug Target."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1038\/srep16589","article-title":"Improved Anti-Glioblastoma Efficacy by IL-13R\u03b12 Mediated Copolymer Nanoparticles Loaded with Paclitaxel","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dash, B.S., Lu, Y.J., Luo, S.H., and Chen, J.P. (2023). Cetuximab-Conjugated Magnetic Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Dual-Targeted Delivery of Irinotecan in Glioma Treatment. Materials, 16.","DOI":"10.3390\/ma16165526"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1166\/jbn.2021.3050","article-title":"Hyaluronic Acid-Conjugated Nanoparticles for the Targeted Delivery of Cabazitaxel to CD44-Overexpressing Glioblastoma Cells","volume":"17","author":"Chen","year":"2021","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12645-021-00078-8","article-title":"Targeting BMI-1 with PLGA\u2013PEG Nanoparticle-Containing PTC209 Modulates the Behavior of Human Glioblastoma Stem Cells and Cancer Cells","volume":"12","author":"Poonaki","year":"2021","journal-title":"Cancer Nanotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/mp400751g","article-title":"RGD and Interleukin-13 Peptide Functionalized Nanoparticles for Enhanced Glioblastoma Cells and Neovasculature Dual Targeting Delivery and Elevated Tumor Penetration","volume":"11","author":"Gao","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.carbpol.2016.09.085","article-title":"Lactoferrin-Coated Polysaccharide Nanoparticles Based on Chitosan Hydrochloride\/Hyaluronic Acid\/PEG for Treating Brain Glioma","volume":"157","author":"Xu","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2022.10.013","article-title":"Dual EGFR- and TfR-Targeted Gene Transfer for Sodium Iodide Symporter Gene Therapy of Glioblastoma","volume":"27","author":"Spellerberg","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Messina, S., Zuchegna, C., and Bruzzi, M. (2025). Chemotherapeutic Nanoparticles for Glioblastoma. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1641752"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug Repurposing for Cancer Therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/1061186X.2019.1706095","article-title":"Intranasal Delivery of Cancer-Targeting Doxorubicin-Loaded PLGA Nanoparticles Arrests Glioblastoma Growth","volume":"28","author":"Chung","year":"2020","journal-title":"J. Drug Target."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"123730","DOI":"10.1016\/j.biomaterials.2025.123730","article-title":"Dual-Responsive Nanoparticle System for Enhanced Blood-Brain Barrier Crossing and Glioblastoma Penetration","volume":"327","author":"Zheng","year":"2026","journal-title":"Biomaterials"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"115023","DOI":"10.1016\/j.biopha.2023.115023","article-title":"Dual Receptor Specific Nanoparticles Targeting EGFR and PD-L1 for Enhanced Delivery of Docetaxel in Cancer Therapy","volume":"165","author":"Emami","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16605","DOI":"10.18632\/oncotarget.15073","article-title":"Anti-GD2-Ch14.18\/CHO Coated Nanoparticles Mediate Glioblastoma (GBM)-Specific Delivery of the Aromatase Inhibitor, Letrozole, Reducing Proliferation, Migration and Chemoresistance in Patient-Derived GBM Tumor Cells","volume":"8","author":"Tivnan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10965","DOI":"10.1021\/acsabm.5c01651","article-title":"Codelivery of Bortezomib and Modified DR5-Selective TRAIL via Amphiphilic Poly(N-Vinylpyrrolidone) Bionanocomposites to Overcome Glioblastoma Resistance","volume":"8","author":"Kukovyakina","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"407","DOI":"10.34172\/PS.2020.94","article-title":"In Vitro Studies of Prednisolone Loaded PLGA Nanoparticles-Surface Functionalized with Folic Acid on Glioma and Macrophage Cell Lines","volume":"27","author":"Acharya","year":"2020","journal-title":"Pharm. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Shen, X., Li, H., Zhang, B., Li, Y., and Zhu, Z. (2025). Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood\u2013Brain Barrier for Alzheimer\u2019s Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199793"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"105714","DOI":"10.1016\/j.jddst.2024.105714","article-title":"Repurposing Gemcitabine for Glioblastoma Treatment: The Role of Drug-Conjugates and Nanoparticles as Drug Delivery Systems","volume":"96","author":"Ramalho","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Zhang, F., Huang, B., Utturkar, S.M., Luo, W., Cresswell, G., Herr, S.A., Zheng, S., Napoleon, J.V., Jiang, R., and Zhang, B. (2024). Tumor-Specific Activation of Folate Receptor Beta Enables Reprogramming of Immune Cells in the Tumor Microenvironment. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1354735"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Kadasah, S.F., Alqahtani, A.M.S., Alkhammash, A., and Radwan, M.O. (2024). Beyond Psychotropic: Potential Repurposing of Fluoxetine toward Cancer Therapy. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202402.0611.v1"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/archneur.1971.00480330094009","article-title":"Corticosteroid Effect on Transplantable Rat Glioma","volume":"24","author":"Gurcay","year":"1971","journal-title":"Arch. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1017\/cjn.2023.276","article-title":"The Value of Etoposide for Recurrent Glioma","volume":"51","author":"Chahal","year":"2024","journal-title":"Can. J. Neurol. Sci.\/J. Can. Des. Sci. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1021\/acs.jmedchem.4c00128","article-title":"Discovery of Novel Small-Molecule-Based Potential PD-L1\/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ezzo, M., and Etienne-Manneville, S. (2025). Microtubule-Targeting Agents: Advances in Tubulin Binding and Small Molecule Therapy for Gliomas and Neurodegenerative Diseases. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157652"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1078-0432.CCR-23-3341","article-title":"A Phase 0\/I Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas","volume":"30","author":"Desai","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Echavidre, W., Picco, V., Faraggi, M., and Montemagno, C. (2022). Integrin-Av\u03b23 as a Therapeutic Target in Glioblastoma: Back to the Future?. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051053"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Cesca, B.A., Caverzan, M.D., Lamberti, M.J., and Ibarra, L.E. (2024). Enhancing Therapeutic Approaches in Glioblastoma with Pro-Oxidant Treatments and Synergistic Combinations: In Vitro Experience of Doxorubicin and Photodynamic Therapy. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202405.2104.v1"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Lu, J., Xu, F., Rao, C., Shen, C., Jin, J., Zhu, Z., Wang, C., and Li, Q. (2022). Mechanism of Action of Paclitaxel for Treating Glioblastoma Based on Single-Cell RNA Sequencing Data and Network Pharmacology. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1076958"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9676","DOI":"10.3390\/curroncol30110702","article-title":"Proteasome Inhibitors against Glioblastoma\u2014Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine","volume":"30","author":"Gozdz","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Artykov, A.A., Belov, D.A., Shipunova, V.O., Trushina, D.B., Deyev, S.M., Dolgikh, D.A., Kirpichnikov, M.P., and Gasparian, M.E. (2020). Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B More Efficiently Than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors. Cancers, 12.","DOI":"10.3390\/cancers12051129"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Shmendel, E.V., Puchkov, P.A., and Maslov, M.A. (2023). Design of Folate-Containing Liposomal Nucleic Acid Delivery Systems for Antitumor Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15051400"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Miner, M.W.G., Liljenb\u00e4ck, H., Virta, J., K\u00e4rn\u00e4, S., Viitanen, R., Elo, P., Gardberg, M., Teuho, J., Saipa, P., and Rajander, J. (2023). High Folate Receptor Expression in Gliomas Can Be Detected In Vivo Using Folate-Based Positron Emission Tomography with High Tumor-to-Brain Uptake Ratio Divulging Potential Future Targeting Possibilities. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1145473"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Todaro, B., Ottalagana, E., Luin, S., and Santi, M. (2023). Targeting Peptides: The New Generation of Targeted Drug Delivery Systems. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061648"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Yan, S., Na, J., Liu, X., and Wu, P. (2024). Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020248"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic Peptides: Current Applications and Future Directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Habib, S., and Singh, M. (2022). Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review. Polymers, 14.","DOI":"10.3390\/polym14040712"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"114789","DOI":"10.1016\/j.colsurfb.2025.114789","article-title":"Metformin Loaded Mn3O4@SiO2 Core\u2013Shell Nanoparticles for Glioblastoma Multiforme Targeted Therapy","volume":"254","author":"Nozhat","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"114998","DOI":"10.1016\/j.colsurfb.2025.114998","article-title":"Poly (Lactic-Co-Glycolic Acid) (PLGA) Nanoparticles for Sustained Release of Metformin Hydrochloride within Cells: A Therapy for Type 2 Diabetes Mellitus","volume":"256","author":"Sun","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2018.08.012","article-title":"Antiglioma via Regulating Oxidative Stress and Remodeling Tumor-Associated Macrophage Using Lactoferrin-Mediated Biomimetic Codelivery of Simvastatin\/Fenretinide","volume":"287","author":"Mo","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41427-019-0138-6","article-title":"Menthol-Modified BSA Nanoparticles for Glioma Targeting Therapy Using an Energy Restriction Strategy","volume":"11","author":"Liang","year":"2019","journal-title":"NPG Asia Mater."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tranon.2016.12.011","article-title":"Dual Functional Mesoporous Silicon Nanoparticles Enhance the Radiosensitivity of VPA in Glioblastoma","volume":"10","author":"Zhang","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40204-022-00209-3","article-title":"Sustained Release of Valproic Acid Loaded on Chitosan Nanoparticles within Hybrid of Alginate\/Chitosan Hydrogel with\/without Stem Cells in Regeneration of Spinal Cord Injury","volume":"12","author":"Jafarimanesh","year":"2023","journal-title":"Prog. Biomater."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Canbolat, F., Demir, N., Yay\u0131ntas, O.T., Pehlivan, M., Eldem, A., Ayna, T.K., and Senel, M. (2024). Chitosan Nanoparticles Loaded with Quercetin and Valproic Acid: A Novel Approach for Enhancing Antioxidant Activity against Oxidative Stress in the SH-SY5Y Human Neuroblastoma Cell Line. Biomedicines, 12.","DOI":"10.3390\/biomedicines12020287"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.18632\/aging.103125","article-title":"Valproic Acid-Labeled Chitosan Nanoparticles Promote Recovery of neuronal Injury after Spinal Cord Injury","volume":"12","author":"Wang","year":"2020","journal-title":"Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CAD.0000000000000197","article-title":"Chemotherapeutic Effect of Tamoxifen on Temozolomide-Resistant Gliomas","volume":"26","author":"He","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF01519896","article-title":"Inhibitory Effects of Tamoxifen and Tumor Necrosis Factor on Human Glioblastoma Cells","volume":"40","author":"Iwasaki","year":"1995","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/1061186X.2015.1132223","article-title":"Enhanced Delivery of Etoposide across the Blood\u2013Brain Barrier to Restrain Brain Tumor Growth Using Melanotransferrin Antibody- and Tamoxifen-Conjugated Solid Lipid Nanoparticles","volume":"24","author":"Kuo","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijpharm.2015.12.054","article-title":"Brain Targeted Delivery of Carmustine Using Solid Lipid Nanoparticles Modified with Tamoxifen and Lactoferrin for Antitumor Proliferation","volume":"499","author":"Kuo","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1016\/j.biomaterials.2012.02.004","article-title":"A Dual-Targeting Nanocarrier Based on Poly(Amidoamine) Dendrimers Conjugated with Transferrin and Tamoxifen for Treating Brain Gliomas","volume":"33","author":"Li","year":"2012","journal-title":"Biomaterials"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jtice.2020.04.014","article-title":"Inhibition of Glioblastoma and Macrophage Phagocytosis Using Sialic Acid-Grafted Tamoxifen-Carmustine-Polyethyleneimine-Poly(Lactic-Co-Glycolic Acid) Nanoparticles","volume":"111","author":"Kuo","year":"2020","journal-title":"J. Taiwan Inst. Chem. Eng."},{"key":"ref_106","first-page":"131","article-title":"Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles","volume":"65","author":"Yadav","year":"2011","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Eltaib, L. (2025). Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers, 17.","DOI":"10.3390\/polym17070833"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e2301838","DOI":"10.1002\/smll.202301838","article-title":"An Overview of Nanoparticle Protein Corona Literature","volume":"19","author":"Hajipour","year":"2023","journal-title":"Small"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e2409635","DOI":"10.1002\/smll.202409635","article-title":"Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds","volume":"21","author":"Adhikari","year":"2025","journal-title":"Small"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/4\/435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:34:59Z","timestamp":1775190899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/4\/435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":109,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["pharmaceutics18040435"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18040435","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}